Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study
Tigecycline is a vital antibiotic treatment option for infections caused by multiresistant bacteria in the intensive care unit (ICU). Acute kidney injury (AKI) is a common complication in the ICU requiring continuous renal replacement therapy (CRRT), but pharmacokinetic data for tigecycline in patie...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 December 2018
|
| In: |
Critical care
Year: 2018, Volume: 22, Pages: 1-7 |
| ISSN: | 1466-609X |
| DOI: | 10.1186/s13054-018-2278-4 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s13054-018-2278-4
|
| Author Notes: | A. Broeker, S.G. Wicha, C. Dorn, A. Kratzer, M. Schleibinger, F. Kees, A. Heininger, M.G. Kees and H. Häberle |
| Summary: | Tigecycline is a vital antibiotic treatment option for infections caused by multiresistant bacteria in the intensive care unit (ICU). Acute kidney injury (AKI) is a common complication in the ICU requiring continuous renal replacement therapy (CRRT), but pharmacokinetic data for tigecycline in patients receiving CRRT are lacking. |
|---|---|
| Item Description: | Gesehen am 14.10.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1466-609X |
| DOI: | 10.1186/s13054-018-2278-4 |